What Is HUTCHMED (China) Limited (HCM) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, HUTCHMED (China) Limited's intrinsic value is estimated at a composite fair value of $9.29. Trading at $11.59, the stock is approaching fair value or slight overvaluation (implied return of -19.9%), as 9 of 13 models suggest limited further upside. The most optimistic model, ML-RIV, places fair value at $35.92 (+210.0%), while Regime Cross — the most conservative — estimates $1.10 (-90.5%). This +300.5% gap reflects genuine analytical uncertainty about HUTCHMED (China) Limited's intrinsic worth. Among models with highest confidence, Markov DDM lean bullish — adding weight to the bullish side of the thesis.
What Do the Models Say About HCM?
13 of 13 models are currently active for HCM. Of these, 4 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates HCM's intrinsic value at $4.19, implying -63.8% downside from the current price. See which stocks rank higher →
How Does HCM Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, HCM ranks #390 by Quality of Company score. CirclFi's QOC score of 2.8/10 evaluates 32 fundamental signals. A score of 2.8 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
HUTCHMED (China) Limited's positioning within the Pharmaceutical Preparations segment means that biosimilar competition timeline plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.
Is HCM a Value Trap?
The Value Trap algorithm is not active for HCM. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for HUTCHMED (China) Limited. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, HUTCHMED (China) Limited scores 2.8 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +300.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every HCM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across HCM's 13 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad